We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Inovio Highlights Clinical and Technology Platforms for DNA Vaccines

Inovio Highlights Clinical and Technology Platforms for DNA Vaccines

Inovio Highlights Clinical and Technology Platforms for DNA Vaccines

Inovio Highlights Clinical and Technology Platforms for DNA Vaccines

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Inovio Highlights Clinical and Technology Platforms for DNA Vaccines "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Inovio Biomedical Corporation has announced that it will deliver four presentations at the American Society for Gene Therapy's 9th Annual Meeting to be held in Baltimore, MD, from May 31 to June 4, 2006.

All four presentations feature applications of Inovio's non-viral technology for delivering DNA into bodily tissues and cells for therapeutic purposes.

The technology, based on the process of electroporation, uses extremely short electrical field pulses to temporarily open cell membranes so that DNA can enter target cells.

Once inside the cells, the DNA can elicit the production of proteins to stimulate an immune response or provide therapeutic gene expression.

In Industrial Liaison: Clinical Developments in Gene Vaccines, workshop #214, Michael Fons, PhD, Inovio's executive director, business development, will review the status of the company's clinical electroporation trials and review the pre-clinical packages and regulatory path Inovio has created for the clinical evaluation of DNA delivery with Inovio's proprietary technology.

Inovio currently supports four human clinical studies in the US and Europe. This workshop will take place on Thursday, June 1, 9:30 a.m. - 11:00 a.m. in room 345/346.

Three other presentations discuss studies relating to Inovio technologies and products in preclinical development:

- Protection Against In Vivo Tumor Growth After Electroporation-Enhanced DNA Vaccination with the Hepatitis C Virus Non-Structural 3/4A will summarize a study conducted with Tripep AB that demonstrated the efficacy of electroporation in enhancing immune responses capable of eliminating HCV-antigen expressing cells.

This poster presentation, #594, was authored by Rune Kjeken, Gustaf Ahlen, Jonas Soderholm, Torunn Tjelle, Iacob Mathiesen, and Matti Sallberg.

- DNA Vaccines: Induction of Humoral and Cellular Responses Via Skin or Muscle Immunization Enhanced by Electroporation will summarize a study that demonstrated the capacity of certain proprietary methods and devices to elicit powerful immune responses with either skin or muscle as the target tissue.

This poster presentation, #597, was authored by Lei Zhang, Georg Widera, Susan Bleecher, and Dietmar Rabussay.

- Feasibility of Cutaneous Gene Therapy Using a Factor VIII Gene and a Marker Gene in Factor VIII-Deficient Mice by Non-Invasive Electroporation will summarize a preclinical study conducted in collaboration with the University of Pennsylvania showing that injection of DNA encoding the blood clotting factor VIII into the skin of hemophilic mice gave rise to the expression of the factor VIII gene.

This poster presentation, #862, was authored by Lei Zhang, Amy Goldbeck, Hongbo Lu, Edward Nolan, Dietmar Rabussay, and Steve Fakharzadeh.

"We are pleased to highlight at this important scientific conference the extent of our development activities," said Avtar Dhillon, MD, president and CEO of Inovio.

"Our pre-clinical data shows the capability of electroporation to enable the potential for DNA vaccines to generate clinically relevant immune responses and for genes to treat protein-deficient diseases such as hemophilia."

"Our aim with the four clinical trials currently being conducted with partners is to establish electroporation as a preferred method of DNA delivery for such applications."

"Inovio pioneered the human clinical use of DNA electroporation and we intend to add partnerships to spearhead new applications and clinical studies using our proprietary technology."